Showing results (651-660 of 834) with videos related to

Sort By:
Pageof 84
JAMA Cardiology|June 14, 2023
Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With FinerenoneRajiv Agarwal, Bertram Pitt, Peter Rossing, et al.
Annals of Internal Medicine|December 5, 2022
Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease : A Post Hoc Analysis of DAPA-CKDMeir Schechter, Niels Jongs, Glenn M Chertow, et al.
Nephron|August 16, 2023
Hepatic Fibrosis Evaluated in Patients with Type 2 Diabetes with and without Chronic Kidney DiseaseTherese Adrian, Mads Hornum, Filip Krag Knop, et al.
Journal of Clinical Medicine|July 9, 2022
Effects of Butyrate Supplementation on Inflammation and Kidney Parameters in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled TrialNinna H Tougaard, Marie Frimodt-Møller, Hanne Salmenkari, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|August 1, 2023
Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of FrailtyPriya Vart, Jawad H Butt, Niels Jongs, et al.
British Journal of Clinical Pharmacology|March 27, 2023
Initiation of glucose-lowering drugs reduces the anticoagulant effect of warfarin-But not through altered drug metabolism in patients with type 2 diabetesAnn-Cathrine Dalgård Dunvald, Flemming Nielsen, Dorte Aalund Olsen, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|September 22, 2022
In vivo molecular imaging of cardiac angiogenesis in persons with and without type 2 diabetes: A cross-sectional 68 Ga-RGD-PET studyJens Christian Laursen, Ida Kirstine Bull Rasmussen, Emilie Hein Zobel, et al.
Diabetes, Obesity & Metabolism|December 10, 2016
Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trialJohn R Petrie, Nish Chaturvedi, Ian Ford, et al.
Circulation|December 14, 2021
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADERAhmed M Shaman, Stephen C Bain, George L Bakris, et al.
Frontiers in Endocrinology|December 30, 2021
The Association Between Cardiovascular Autonomic Function and Changes in Kidney and Myocardial Function in Type 2 Diabetes and Healthy ControlsJens Christian Laursen, Ida Kirstine B Rasmussen, Emilie H Zobel, et al.
Pageof 84